To identify effector miRNAs of the PI3K/AKT pathway, the NSCLC cell line PC9 containing a constitutive active EGFR mutation was treated with the PI3K inhibitor LY294002 and changes in global miRNA expression was assessed using the NanoString technology. This evidence concerns the gene EGFR and non-small cell lung carcinoma.